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Objective: A regional ‘Be Clear on Cancer’ (BCoC) campaign developed by Public
Health England aimed to promote public awareness of key abdominal cancer symp-
toms in people aged 50 years and over.
Methods: Data were analysed for metrics at different stages in the patient care path-
way including public awareness, GP attendance and referrals, to cancer diagnosis.
Results: There was significantly higher recognition of the BCoC abdominal campaign
in the campaign region compared to the control area (Post Campaign/Control,
n = 401/406; 35% vs. 24%, p < 0.05). The campaign significantly improved knowl-
edge of ‘bloating’ as a symptom (p = 0.03) compared to pre-campaign levels. GP
attendances for abdominal symptoms increased significantly by 5.8% (p = 0. 03),
although the actual increase per practice was small (average 16.8 visits per week in
2016 to 17.7 in 2017). Urgent GP referrals for suspected abdominal cancer increased
by 7.6%, compared to a non-significant change (0.05%) in the control area. For spe-
cific abdominal cancers, the number diagnosed were similar to or higher than the
median in the campaign area but not in the control area in people aged 50 and over:
colorectal (additional n = 61 cancers), pancreatic (additional n = 102) and stomach
cancers (additional n = 17).
Conclusions: This campaign had a modest impact on public awareness of abdominal
cancer symptoms, GP attendances and cancers diagnosed.
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1 | INTRODUCTION
Approximately half of all cancers diagnosed and registered in the UK
(excluding non-melanoma skin cancer) are situated in the abdominal
cavity (Information Service Division of NHS Scotland, 2017; Office for
National Statistics, 2017). In primary care, patients presenting with
abdominal and digestive symptoms account for 10%–15% of consul-
tations with general practitioners (GPs) (Elliott et al., 2011; Holtedahl
et al., 2017; Information Services Division of NHS Scotland, 2013),
and diagnosis of cancer can prove challenging (Holtedahl et al., 2017;
Lyratzopoulos et al., 2014; Rubin et al., 2015). Abdominal symptoms
have been found to be significantly associated with a new cancer
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diagnosis in the abdominal region (Holtedahl et al., 2017; Scheel &
Holtedahl, 2015), and there are several recurrent symptoms that are
reported for different types of abdominal cancer. For example, symp-
toms such as diarrhoea, abdominal discomfort and bloating have all
been reported as indicators of colorectal, ovarian and pancreatic can-
cer (Hamilton et al., 2016; Koo, Hamilton, et al., 2018; Walter, Emery,
et al., 2016; Walter, Mills, et al., 2016).
Although UK cancer survival has been improving steadily since
the 1970s (Arnold et al., 2019; Quaresma et al., 2015) and can be
comparable to other high-income countries, international disparities
do persist (Allemani et al., 2018; Arnold et al., 2019; Bankhead, 2017).
More advanced cancer stage at diagnosis is a significant contributor
to reduced survival, as are poorer stage-specific survival and higher
rates of co-morbidity (Coleman et al., 2011; Maringe et al., 2013).
Low cancer symptom awareness contributes to delay in presenta-
tion and may lead to delay in cancer diagnosis (McCutchan et al.,
2015; Rendle et al., 2019; Simon et al., 2010). Approaches to promote
early presentation in general practice aim to increase awareness of
the significance of cancer symptoms, and it has been suggested that
they should be specifically designed to work for people of the lowest
socioeconomic status (Forbes et al., 2014). Cancer awareness cam-
paigns aim to educate the public about cancer symptoms and encour-
age help-seeking and could play a role in promoting early diagnosis
(Simon et al., 2010) by shortening the interval between symptom
onset and presentation to a doctor thereby potentially improving
patients' prognosis (Smith et al., 2018).
There is some evidence that community-level interventions, to
increase public awareness, may lead to earlier diagnosis at stage of
presentation for specific cancers (breast cancer, malignant melanoma,
retinoblastoma and lung cancer) in the short term (Austoker
et al., 2009; Ironmonger et al., 2015). Based on the success of
previous campaigns run under the ‘Be Clear on Cancer’ brand,
(Ironmonger et al., 2015; Moffat et al., 2015), a regional campaign was
developed by Public Health England (PHE) and aimed to promote pub-
lic awareness of key abdominal symptoms in people aged 50 and over
and involved regional TV as well as distribution of messages via bus
stop posters and billboards. The core campaign message was, ‘Don't
ignore the warning signs. If you've been suffering from tummy trou-
bles such as diarrhoea, bloating, discomfort or anything else that just
doesn't feel right for three weeks or more, it could be a sign of cancer.
Finding it early makes it more treatable. Tell your doctor’. This paper
aims to evaluate the impact of the regional campaign on public aware-
ness of abdominal symptoms, number of patients presenting to a GP
with symptoms, subsequent referrals and cancers diagnosed.
2 | METHODS
2.1 | Sample and setting
The regional abdominal symptoms campaign ran from 9 February to
31 March 2017 in the East and West Midlands in England.
The regional campaign area was selected for a number of
reasons: it was populous enough to support accurate campaign
evaluation, the area had a mix of urban and rural areas and demo-
graphically the region is reasonably representative of the national
population. Background research with the target audience was
undertaken during the development phase, leading on to the
approach to include symptoms in the context of a body area
(abdomen), and that are associated with a number of different
tumour types. This was developed on the basis that advertising
this group of symptoms would achieve both a high level of reach
among the target audience, while broadening the potential number
of cancers associated with the campaign. The advertising approach
and messaging were developed and tested with the target
audience (men and women over 50 years of age) and refined to
ensure that campaign advertising was focused and clearly commu-
nicated. There was significant input from clinical and marketing
experts, and the final advertising was reviewed by clinical experts
for accuracy and appropriateness. The local Strategic Clinical Net-
works supported the campaign. Strategic Clinical Networks work in
partnership with commissioners, providers and voluntary organisa-
tions as a vehicle for improvement for patients, carers and the
public.
2.2 | Data
To evaluate the impact of the regional campaign, data were obtained
and analysed for a range of metrics outlined below. These represent
the various stages of the patient care pathway including symptom
recognition, consultation with a health professional, referral and
diagnosis.
Data were obtained from a range of existing national datasets,
each described below. The main analyses for each metric compared
the period during and/or immediately after the campaign (analysis
period) with a period prior to the campaign (often the same months as
the analysis period in the previous year, or the median for the previ-
ous year) (comparison period). The exact periods used varied across
metrics, dependent on data availability and clinician recommenda-
tions, and these are detailed in Table 1.
Data were also sourced for a control geographic area (South East
England—unless otherwise specified) for each of the metrics. South
East England was chosen as a control as it has a similar demographic
profile (e.g. age, sex and deprivation) to East and West Midlands,
although the campaign area had a larger population overall
(10,632,372 in campaign area and 9,080,825 in control area in 2017).
For GP attendances, rather than a control area, a control symptom
(Back pain) was evaluated. Back pain was chosen as a control symp-
tom as GP attendances for this symptom were unlikely to be affected
by the campaign messaging. It was hypothesised that changes in
controls represent any background trends, and any changes around
the campaign period that were greater than controls may suggest a
campaign impact.
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2.2.1 | Public awareness
To determine whether there were differences in public awareness of
abdominal symptoms, before and after the campaign, pre- and post-
campaign online and face-to-face interviews were undertaken by
Kantar Public on behalf of PHE. These data were collected from resi-
dents in the regional campaign area and from a comparative control
group (rest of England). The evaluation sample comprised of adults
aged 50–89 year and were weighted to age, gender, social grade and
region profile within the pilot and control regions. Participants were
firstly asked about awareness of abdominal symptoms for possible
cancer and then specifically about awareness of the campaign
including radio adverts, poster and leaflets in health care setting
(e.g. doctor's surgery and pharmacies).
2.2.2 | GP attendances
Data on GP attendances for abdominal symptoms and a control symp-
tom (back pain) for those aged 50 and over were sourced from The
Health Improvement Network (THIN) database for the period
14 September 2015 to 9 July 2017 (The Health Improvement
Network (THIN) database, 2017). The data were grouped into weeks
(based on International Organisation for Standardisation [ISO] week)
and adjusted to account for bank holidays and for a 5-day working
week (International Organization for Standardization, 2017). Informa-
tion on the number of GP practices from the campaign area submitting
data to THIN each week (ranging from 37 to 16) was also extracted to
enable calculation of the average number of attendances per practice
per week. Compared to all practices nationally, these practices had a
similar age-sex population structure, but a less deprived population on
average. Relevant symptoms were identified using a clinically-advised
set of NHS Digital (2016) a standard clinical terminology system used
by GP systems during the time period of the study (full list of Read
Codes available in the supporting information).
2.2.3 | Urgent GP referrals for suspected cancer
The monthly number of urgent GP referrals for suspected abdominal
cancers for those aged 50 and over for the period January 2015 to
August 2017 were obtained from the National Cancer Waiting Times
Monitoring Data Set, provided by NHS England. Data were analysed
as suspected gynaecological, urological, upper gastro-intestinal
(GI) and lower GI cancers, and all four suspected cancers combined.
Results are presented by the month that a patient was first seen in
secondary care following referral.
2.2.4 | Diagnostics in secondary care
The monthly number of imaging tests conducted from GP direct access
only for suspected abdominal cancers between January 2016 and
June 2017 was obtained from the Diagnostic Imaging Dataset (2017).
2.2.5 | Cancers diagnosed
The weekly numbers of newly diagnosed abdominal cancers (through
all diagnostic routes) among those aged 50 and over were obtained
from the National Cancer Registration dataset in England (Henson
et al., 2020) for the period October 2016 to September 2017. Number
of cancers were based on ISO week and adjusted for bank holidays
(International Organization for Standardization, 2017).
TABLE 1 Analysis and comparison periods used for each clinical metric in main analyses and further analyses
Metric Comparison period Analysis period Data source
GP attendances Pre-campaign period: 23
November 2015 to 14 February
2016
Pre-campaign period: 21
November 2016 to 12 February
2017
The Health Improvement Network
(THIN) database (Network)
Campaign period: 15 February
2016 to 17 April 2016
Campaign period: 13 February
2017 to 16 April 2017
Post-campaign period: 18 April
2016 to 10 July 2016
Post-campaign period: 17 April
2017 to 9 July 2017
Urgent GP referrals for
suspected abdominal cancer
February to April 2016 February to April 2017 National Cancer Waiting Times
Monitoring Data Set, NHS
England
Diagnostics in secondary care February to May 2016 February to May 2017 Diagnostic Imaging Dataset, NHS
England
Cancers diagnosed Overall median for October 2016
to September 2017
20 February 2017 to 4 June 2017 National Cancer Registration
dataset
Note: The exact dates are provided for metrics which had weekly data available. The Health Improvement Network (THIN) database (Network) https://
www.the-health-improvement-network.com/en/#what-is-thin. National Cancer Waiting Times Monitoring Data Set, NHS England https://digital.nhs.uk/
data-and-information/data-collections-and-data-sets/data-collections/cancerwaitingtimescwt. Diagnostic Imaging Dataset, NHS England https://www.
england.nhs.uk/statistics/statistical-work-areas/diagnostic-imaging-dataset/. National Cancer Registration dataset (Henson et al., 2020).
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Data relating to abdominal cancers were identified using Interna-
tional Classification of Diseases Version 10. Data analyses included
codes for both individual cancer sites and combined abdominal can-
cers groups: colorectal (ICD10 C18-C20), kidney (C64-C66, C68),
oesophageal (C15), ovarian (C56-C57, C48 non-sarcoma), pancreatic
(C25), and stomach (C16) cancers, and where appropriate in combina-
tion as lower gastro- intestinal (GI) (ICD10 C17-C21, C26) and upper
GI (C15-C16, C22-C25).
2.3 | Statistical analysis
For all metrics, excluding cancers diagnosed, weekly and monthly
counts or percentages were aggregated over the analysis and compari-
son periods, and a statistical test was used to test for any differences
between the two periods. A two-sample t-test was used to test for
statistical significance of aggregated proportion between two periods
for the metric Public awareness. A likelihood ratio test was used to test
for statistical significance of aggregated counts for the metrics GP
attendances and urgent GP referrals for suspected cancer. A two-sided t-
test adjusted for unequal variances, if required, was used to test for
statistical significance of aggregated counts for the metric diagnostics
in secondary care. For cancers diagnosed, the campaign was considered
to have had a possible impact if (1) the numbers of cases per week
were the same or higher than the median for five or more consecutive
weeks (under the premise that there is a 50% chance that a weekly
count is higher or lower than the median, therefore five consecutive
weeks equal to or above the median [one-tailed] equates a p = 0.031)
and (2) this sustained period started during the analysis period based
on ISO week. A p-value <0.05 was considered to be statistically signif-
icant throughout the analysis. All statistical analyses were carried out
in Stata version 15.0 (StataCorp, 2017).
For metrics where the main analysis used data on people ages
50 years and over, sensitivity analyses examined persons of any age,
where possible.
Full details of the methodology used for the analysis can be found
on the National Cancer Registration and Analysis Service website
(Public Health England, 2019).
3 | RESULTS
3.1 | Public awareness
When asked if they were aware of any adverts, publicity or other
information about ‘tummy troubles … for three weeks or more’, there
was significantly higher campaign recognition in the regional campaign
compared to the control area (post-campaign/control, n = 401/406;
35% vs. 24%, p < 0.005). With regard to specific abdominal symp-
toms, the campaign significantly improved knowledge that ‘bloating’
(p = 0.03) and ‘feeling sick/nauseous’ (p = 0.03) could be a sign of
something serious, whereas this was not seen in the control region
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discomfort or other symptoms within the campaign area or compared
with the control area.
3.2 | GP attendances
For patients aged 50 and over, there were significant increases in
post-campaign GP attendances per practice per week for all abdomi-
nal symptoms (p < 0.001), for diarrhoea (p = 0.014) and for discomfort
(p = 0.018), compared to the same period in 2016. Presentations for
bloating increased during the campaign period from 0.4 visits in 2016
to 0.6 visits per GP practice per week during the same period in
2016 (p = 0.003) (Table 3).
3.3 | Urgent GP referrals for suspected abdominal
cancers
For all suspected abdominal cancers combined, there was a statisti-
cally significant 8.1% increase in the number of urgent GP referrals for
suspected cancer from 35,845 in February to April 2016, to 38,737
cases in the same period in 2017 (p < 0.001). There was a significant,
18.0% increase in referrals for suspected lower GI cancers (12,046
cases to 14,214 cases, p < 0.001), 5.4% increase in referrals for
suspected upper GI cancers (8759 to 9327 cases; p < 0.001) and 5.0%
increase in referrals for suspected gynaecological cancer (5681 cases
to 5966 cases; p = 0.008). These changes are compared with non-
significant changes in the control area, where the only significant
increase observed for urgent referrals for suspected lower GI cancer
(8.7% change; p < 0.001). The number of urgent GP referrals
for suspected abdominal cancers combined and for suspected
gynaecological, urological, upper GI and lower GI cancers, for people
aged 50 and over in the regional campaign and control areas, are
shown in Table 4.
3.4 | Diagnostics in secondary care
For individuals aged 50 and over, there was a 0.3% decrease (150,760
to 150,265) in the number of imaging tests from GP direct access in
February to May 2017, compared to these months in the previous
year, although not statistically significant. There were also no signifi-
cant changes in the number of diagnostic tests found in the
control area.
3.5 | Cancers diagnosed
The numbers of all abdominal cancers within the regional campaign
area were similar to, or higher than, the 2016–2017 median for the
five-week period at weeks 18–22 in 2017 (mid-May to mid-June
2017), for persons aged 50 and over. This increase above the median
also appears to have been sustained for a longer period in the control
area (Figure S1).
Within the analysis period, an additional 97 cases were diagnosed
compared with the expected number based on the median (1388
cases) for persons aged 50 and over (Table S1). In the control area,
similar increases were observed with 176 additional abdominal
TABLE 3 Regional campaign: presentations per GP practice per week for patients aged 50+
Presentations per practice per week (adjusteda)





Bloating Pre-campaign 0.39 0.28 0.11 28.4 0.037
Campaign 0.36 0.57 0.21 58.8 0.003
Post-campaign 0.37 0.48 0.11 31.5 0.074
Diarrhoea Pre-campaign 1.91 1.98 0.07 3.7 0.574
Campaign 2.11 2.23 0.12 5.7 0.443
Post-campaign 1.95 2.31 0.36 18.3 0.014
Discomfort Pre-campaign 4.27 4.40 0.13 3.0 0.502
Campaign 4.45 4.36 0.09 2.1 0.672
Post-campaign 3.86 4.34 0.48 12.3 0.018
Combined abdominal
symptoms
Pre-campaign 6.54 6.64 0.10 1.5 0.673
Campaign 6.87 7.10 0.23 3.3 0.409
Post-campaign 6.15 7.14 0.99 16.1 <0.001
Control symptom
(back pain)
Pre-campaign 5.75 5.63 0.12 2.2 0.561
Campaign 6.57 6.06 0.51 7.7 0.058
Post-campaign 5.78 6.26 0.48 8.3 0.050
Note: Pre-campaign period: 12 weeks from 21 November 2016. Campaign period: 9 weeks from 13 February 2017. Post-campaign period: 12 weeks from
17 April 2017. Results in bold indicate a statistically significant change between 2016 and 2017 (likelihood ratio test of two counts; p < 0.05).
aAnalysis based on ISO week, adjusted for a 5-day working week excluding bank holidays.
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cancers (1859 compared to 168 median), comparing weeks 14 to
20 in 2017 (Table S1).
The numbers of colorectal, pancreatic and stomach cancers were
similar to, or higher than, the 2016–2017 median for people aged
50 years and over for five or more consecutive weeks in the regional
campaign area (Figure 1). There were an additional 61 colorectal can-
cers diagnosed compared with the expected number (based on the
median of 1056 cases); an additional 102 pancreatic cancers diagnosed
(based on median 284 cases), and for stomach cancer there were an
additional 17 cancers diagnosed (based on median of 126 cases)
(Table S1). There was no sustained increase observed in the control
area for these cancers diagnosed in people aged 50 years and over.
There were no sustained periods where the numbers of
oesophageal or ovarian cancers were the same as or higher than the
2016-to-2017 median for either the regional campaign area or control
area for people aged 50 years and over (Figure 1).
3.6 | Sensitivity analysis
Sensitivity analyses examining persons of any age revealed similar
results to the main analyses restricted to people ages 50 years and
over (Tables S1–S3). However, the increase in GP attendances for
combined abdominal symptoms during the campaign period reached
statistical significance (5.8% increase, p = 0.026) in addition to the
increase observed in the post-campaign period (also observed for per-
sons aged 50 years and over).
4 | DISCUSSION
This regional ‘Be Clear on Cancer’ campaign for abdominal symptoms
was aimed at people aged 50 years and over to encourage symptom
awareness, and early presentation in primary care. Overall, the find-
ings suggest that there was some evidence of an increase in public
awareness of symptoms and a modest increase in the number of GP
attendances, which may have had an impact on the number of urgent
GP referrals for suspected cancer. There was no evidence of a signifi-
cant impact on the number of diagnostic tests carried out in second-
ary care; however, there may be variation in Diagnostic Imaging
Dataset coverage over the analysis period. For people over 50 years,
additional cancers for pancreas, stomach and colorectal were diag-
nosed in the campaign region, but no sustained increases were
observed in the control area.
Patients presenting with symptoms are typical and important
drivers of primary care use (McAteer et al., 2011). In a qualitative
TABLE 4 Number of urgent GP referrals for suspected abdominal cancers combined, and for suspected gynaecological, urological, upper GI
and lower GI cancers for people age 50 ± in the regional campaign and control areas
Referral type Area Year
February–April





Regional campaign 2016 35,845 8.1 <0.001 3791.9 (3752.5, 3831.7)
2017 38,737 4216.7 (4174.5, 4259.2)
Control 2016 28,439 0.3 0.678 3544.7 (3503.3, 3586.5)
2017 28,538 3659.3 (3616.6, 3702.3)
Gynaecological Regional campaign 2016 5681 5.0 0.008 570.3 (555.6, 585.4)
2017 5966 617.9 (602.3, 633.8)
Control 2016 4445 1.5 0.476 523.9 (508.5, 539.6)
2017 4378 532.7 (517.0, 548.8)
Urological Regional campaign 2016 9359 0.3 0.815 1029.2 (1008.3, 1050.5)
2017 9327 1055.5 (1034.0, 1077.3)
Control 2016 7783 7.6 <0.001 1015.9 (993.3, 1038.9)
2017 7190 965.5 (943.1, 988.2)
Upper GI Regional campaign 2016 8759 5.4 <0.001 920.8 (901.4, 940.4)
2017 9230 1000.4 (979.9, 1021.2)
Control 2016 6456 1.4 0.422 799.2 (779.7, 819.1)
2017 6365 808.8 (788.9, 829.1)
Lower GI Regional campaign 2016 12,046 18.0 <0.001 1271.6 (1248.8, 1294.7)
2017 14,214 1542.9 (1517.5, 1568.7)
Control 2016 9755 8.7 <0.001 1205.7 (1181.6, 1230.1)
2017 10,605 1352.3 (1326.4, 1378.5)
*p-values from a likelihood ratio test; significant results for increases shown in bold.
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study of patients recently diagnosed with lung or bowel cancer, par-
ticipants reported difficulties in interpreting diffuse bodily sensations
and symptoms and deciding when to consult (MacArtney et al., 2017).
Abdominal symptoms are often unspecific and may be vague. How-
ever, they are the main reason for patient attendance in 10%–15% of
GP consultations and have been found to be significantly associated
with a new abdominal cancer diagnosis (Holtedahl et al., 2018).
The abdominal symptoms campaign marked a strategic approach
for the ‘Be Clear on Cancer’ brand with a broadening of the campaign
message that aimed to raise public awareness about the symptoms
related to a number of different abdominal cancers, including some
less common cancers. Previous campaigns focused on raising aware-
ness of signs and symptoms of specific cancer sites, such as lung can-
cer (Ironmonger et al., 2015). In the abdominal symptoms campaign, it
is also likely that some GP referrals for suspected gynaecological and
urological cancers were made due to concerns about other symptoms,
including bleeding, which was not a component of the campaign
message.
Awareness-raising campaigns can increase knowledge of the dis-
ease and attendance at health services in the short-term, however
those at lower risk are often the ones to respond, and evidence of
longer-term impact is very limited (Austoker et al., 2009). In previous
research, GPs were generally positive about an intervention to
improve patients' awareness of gynaecological cancers but had con-
cerns about increasing rates of attendance (Evans et al., 2014). GPs
have previously reported that public health cancer awareness initia-
tives often resulted in extra consultations and investigations due to
increased demand from patients they collectively termed ‘the worried
well’ and that the campaign messages often missed their target audi-
ence (Green et al., 2016). It is possible that the campaign changed
awareness and behaviour in GPs themselves, in addition to the public,
although this was beyond the remit of this evaluation, future research
may look to explore this. In this evaluation, there was a small increase
in the average number of additional attendances during and after the
campaign (one additional patient per GP practice per week) suggesting
that the burden on the NHS primary care is limited. There was an
increase in the number of urgent referrals but not diagnostic tests,
which may have specific capacity issues (e.g. for specialist consulta-
tions) for the NHS. Further research is needed to quantify the benefits
of increasing awareness of abdominal symptoms against resource
costs such as referrals, increased consultations and investigations.
The data on health service utilisation were provided from a num-
ber of reliable sources of NHS routinely collected electronic data and
have been used in previous evaluations (Ironmonger et al., 2015).
F IGURE 1 Number of newly diagnosed cases of cancer by abdominal site: week, October 2016 to September 2017, for patients 50 years and
over in the campaign and control areas
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There are limitations within these sources. For GP attendances, data
were obtained from a variable sample of practices sourced from the
THIN database, for which, although they had similar sociodemo-
graphic characteristics, there may be unknown differences. Deprived
populations are less likely to seek healthcare and are therefore likely
to be underrepresented. Furthermore, the accuracy of these data
relies on GPs precisely recording abdominal symptoms in the patient's
medical record and that appropriate Read Codes are assigned. The
observational design and cross-sectional nature of the metrics affect
the extent to which the results presented can be definitively linked to
the campaign. The analysis period for cancers diagnosed was defined
as 2 weeks after the start of the campaign to 2 months after the end.
This relatively short timeframe has been used in previous campaign
evaluations (Lai et al., 2021). It is possible that some patients attended
their GP practice were referred and diagnosed towards the end of
the campaign period, and this could potentially have resulted in
under-counting of abdominal cancers related to the awareness
campaign. The data included in this paper include cancers diagnosed
through all diagnostic routes, including urgent GP referral for
suspected cancer and the proportions of cancers diagnosed through
an emergency presentation. The campaign did not appear to have
an impact on these metrics individually; therefore, all cancers diag-
nosed within the specified timescales in relation to the campaign
period were included in the data analysis. For many cancers, inci-
dence has been increasing over the last few decades; therefore, an
increase in the number of cancers diagnosed may have been
expected irrespective of the campaign. However, this evaluation
observed an increase in several cancers in the campaign region but
not in the control area, suggesting that any increases observed were
not solely due to long-term trends.
Separately, a national screening programme for colorectal cancers
already exists in the NHS in England, with tests routinely offered to
over 55s (Cancer Research UK, 2017). The main focus in the campaign
reported in this paper was not to increase screening but to increase
awareness of a number of abdominal symptoms related to cancer
diagnoses. Increasing uptake of colorectal screening has been the
focus of a separate campaign which ran in North West England,
evaluation showed uptake was significantly increased.
Common presenting symptoms for cancers with a broad
‘symptom signature’ have been reported for a number of abdomi-
nal cancers that were included in this BCoC campaign (Koo,
Hamilton, et al., 2018), and it is suggested that public health edu-
cation campaigns could provide more information on symptom
combinations. Previous BCoC campaigns focused on symptoms
that relate to one cancer site (e.g. breast and lung) and have also
been shown to be successful (Holland et al., 2019; Ironmonger
et al., 2015) although we cannot speculate, from the data pres-
ented in this paper, that one strategy is better than the other.
Early diagnosis initiatives such as public health campaigns aimed at
raising awareness of possible symptoms of cancer and clinical
guidelines for the assessment and investigation of patients with
symptoms have the potential to help detect cancer at a non-
advanced stage (Koo et al., 2020).
5 | CONCLUSIONS
This regional campaign had a modest impact on public awareness of
abdominal cancer symptoms that are common to different types
of cancer of the abdomen. There was some evidence of a patient
impact on early parts of the care pathway, including increased aware-
ness of some abdominal symptoms, an increase in the number of GP
attendances and cancers diagnosed with abdominal symptoms, and in
GP referrals for further investigation. It appears that there may have
been an impact on the number of colorectal, kidney, pancreatic and
stomach cancers diagnosed but not on the number of oesophageal or
ovarian cancers diagnosed. Future evaluations should investigate
campaign impact by socio-economic status.
ACKNOWLEDGMENTS
This work uses data that has been provided by patients and collected
by the NHS as part of their care and support. These data are collated,
maintained and quality assured by the National Cancer Registration
and Analysis Service, which is part of Public Health England (PHE).
PHE leads the Be Clear on Cancer programme working in partnership
with the Department of Health and Social Care, NHS England and
Improvement, and a number of cancer charities. The Early Diagnosis
team at Cancer Research UK did the original scoping for the Be Clear
on Cancer generic/multi-cancer approach on which the abdominal
symptoms campaign was built. We thank the following individuals for
their contributions to the campaign evaluation and advice on the man-
uscript: Emma Logan and Miriam Miller from PHE Marketing; Jodie
Moffat from Cancer Research UK; Isobel Tudge, Ravneet Sandhu,
Kwok Wong, Jennifer Lai and Christopher Lawrence from PHE
NCRAS who completed parts of the initial analysis; Osa Adeghe, facili-
tated improved drafts and provided supportive admin and QA work;
Lizz Paley and Georgios Lyratzopoulos, for their formative feedback
and advice in an early draft of the paper. The Be Clear on Cancer
Programme is led by Public Health England, delivered in partnership
with NHS England, Departments of Health and Social Care, and
Cancer Research UK.
CONFLICT OF INTERESTS
All authors have no conflict of interests to report.
AUTHOR CONTRIBUTIONS
Contributed to the project evaluation design and/or implementation:
CB, HH, JF, VM, CG and LE-B. Statistical analysis and statistical
advice: CB, VM and NT. First draft and submission draft: NT. Critical
data review, comments on all subsequent drafts, final version of man-
uscript approval: all authors.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available at http://
www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific
_work/be_clear_on_cancer/abdominalsymptomsevaluationresults. The
row-level data used in initial analyses are not publicly available due to
privacy or ethical restrictions.
8 of 10 TORRANCE ET AL.
ORCID
Nicola Torrance https://orcid.org/0000-0002-7856-7408




Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Niksic, M.,
Bonaventure, A., Valkov, M., Johnson, C. J., Esteve, J., Ogunbiyi, O. J.,
Azevedo, E., Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A.,
Monnereau, A., Woods, R. R., … Concord Working Group.
(2018). Global surveillance of trends in cancer survival 2000-14
(CONCORD-3): Analysis of individual records for 37 513 025 patients
diagnosed with one of 18 cancers from 322 population-based regis-
tries in 71 countries. The Lancet, 391(10125), 1023–1075. https://doi.
org/10.1016/S0140-6736(17)33326-3
Arnold, M., Rutherford, M. J., Bardot, A., Ferlay, J., Andersson, T. M.,
Myklebust, T. A., & Bray, F. (2019). Progress in cancer survival, mortal-
ity, and incidence in seven high-income countries 1995-2014 (ICBP
SURVMARK-2): A population-based study. Lancet Oncology, 20(11),
1493–1505. https://doi.org/10.1016/S1470-2045(19)30456-5
Austoker, J., Bankhead, C., Forbes, L. J., Atkins, L., Martin, F., Robb, K.,
Wardle, J., & Ramirez, A. J. (2009). Interventions to promote cancer
awareness and early presentation: Systematic review. British Journal
of Cancer, 101(Suppl 2), S31–S39. https://doi.org/10.1038/sj.bjc.
6605388
Bankhead, C. (2017). The 2-week wait and other initiatives to improve
cancer diagnosis: Has it altered survival? The answer is unclear-the
evidence is too weak. European Journal of Cancer Care, 26(3), e12712.
https://doi.org/10.1111/ecc.12712




Coleman, M. P., Forman, D., Bryant, H., Butler, J., Rachet, B.,
Maringe, C., & The International Cancer Benchmarking Partnership
Group. (2011). Cancer survival in Australia, Canada, Denmark, Norway,
Sweden, and the UK, 1995-2007 (the International Cancer
Benchmarking Partnership): an analysis of population-based
cancer registry data. Lancet, 377(9760), 127–138. https://doi.org/10.
1016/S0140-6736(10)62231-3
Diagnostic Imaging Dataset. (2017). NHS England. https://www.england.
nhs.uk/statistics/statistical-work-areas/diagnostic-imaging-dataset/
Elliott, A. M., McAteer, A., & Hannaford, P. C. (2011). Revisiting the
symptom iceberg in today's primary care: Results from a UK popula-
tion survey. BMC Family Practice, 12, 16. https://doi.org/10.1186/
1471-2296-12-16
Evans, R. E. C., Morris, M., Sekhon, M., Buszewicz, M., Walter, F. M.,
Waller, J., & Simon, A. E. (2014). Increasing awareness of
gynaecological cancer symptoms: A GP perspective. British Journal of
General Practice, 64(623), E372–E380. https://doi.org/10.3399/
bjgp14X680161
Forbes, L. J. L., Warburton, F., Richards, M. A., & Ramirez, A. J. (2014). Risk
factors for delay in symptomatic presentation: a survey of cancer
patients. British Journal of Cancer, 111, 581–588. https://doi.org/10.
1038/bjc.2014.304
Green, T., Atkin, K., & Macleod, U. (2016). GPs' perceptions and experi-
ences of public awareness campaigns for cancer: A qualitative enquiry.
Health Expectations, 19(2), 377–387. https://doi.org/10.1111/hex.
12362
Hamilton, W., Walter, F. M., Rubin, G., & Neal, R. D. (2016). Improving
early diagnosis of symptomatic cancer. Nature Reviews Clinical Oncol-
ogy, 13(12), 740–749. https://doi.org/10.1038/nrclinonc.2016.109
Henson, K. E., Elliss-Brookes, L., Coupland, V. H., Payne, E., Vernon, S.,
Rous, B., & Rashbass, J. (2020). Data resource profile: National Cancer
Registration Dataset in England. International Journal of Epidemiology,
49(1), 16–16h. https://doi.org/10.1093/ije/dyz076
Holland, S., et al. Be Clear on Cancer: National breast cancer in women
over 70 awareness campaigns 2014 and 2015. Final evaluation results.
(2019). Crown copyright 2019 http://www.ncin.org.uk/cancer_type_
and_topic_specific_work/topic_specific_work/be_clear_on_cancer/
Holtedahl, K., Hjertholm, P., Borgquist, L., Donker, G. A., Buntinx, F.,
Weller, D., Braaten, T., Mansson, J., Strandberg, E. L., Campbell, C.,
Korevaar, J. C., & Parajuli, R. (2018). Abdominal symptoms and cancer
in the abdomen: Prospective cohort study in European primary care.
British Journal of General Practice, 68(670), e301–e310. https://doi.
org/10.3399/bjgp18X695777
Holtedahl, K., Vedsted, P., Borgquist, L., Donker, G. A., Buntinx, F.,
Weller, D., Braaten, T., Hjertholm, P., Mansson, J., Strandberg, E. L.,
Campbell, C., Ellegaard, L., & Parajuli, R. (2017). Abdominal symptoms
in general practice: Frequency, cancer suspicions raised, and actions
taken by GPs in six European countries. Cohort study with prospective
registration of cancer. Heliyon, 3(6), e00328. https://doi.org/10.1016/
j.heliyon.2017.e00328
Information Service Division of NHS Scotland (ISD). (2017). Cancer Statis-
tics. Cancer Incidence in Scotland 2017. Available at: https://www.
isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/
Information Services Division of NHS Scotland (2013). Reason for Con-
sulting the GP Practice. Available at: https://www.isdscotland.org/
Health-Topics/General-Practice/GP-Consultations/
International Organization for Standardization (ISO). (2017). Available at:
https://www.iso.org/home.html
Ironmonger, L., Ohuma, E., Ormiston-Smith, N., Gildea, C.,
Thomson, C. S., & Peake, M. D. (2015). An evaluation of the impact of
large-scale interventions to raise public awareness of a lung cancer
symptoms. British Journal of Cancer, 112(1), 207–216. https://doi.org/
10.1038/bjc.2014.596
Koo, M. M., Hamilton, W., Walter, F. M., Rubin, G. P., & Lyratzopoulos, G.
(2018). Symptom signatures and diagnostic timeliness in cancer
patients: A review of current evidence. Neoplasia, 20(2), 165–174.
https://doi.org/10.1016/j.neo.2017.11.005
Koo, M. M., Swann, R., McPhail, S., Abel, G. A., Elliss-Brookes, L.,
Rubin, G. P., & Lyratzopoulos, G. (2020). Presenting symptoms of can-
cer and stage at diagnosis: Evidence from a cross-sectional,
population-based study. The Lancet. Oncology, 21(1), 73–79. https://
doi.org/10.1016/S1470-2045(19)30595-9
Koo, M. M., von Wagner, C., Abel, G. A., McPhail, S., Hamilton, W.,
Rubin, G. P., & Lyratzopoulos, G. (2018). The nature and frequency of
abdominal symptoms in cancer patients and their associations with
time to help-seeking: Evidence from a national audit of cancer diagno-
sis. Journal of Public Health (Oxf), 40(3), e388–e395. https://doi.org/
10.1093/pubmed/fdx188
Lai, J., Mak, V., Bright, C. J., Lyratzopoulos, G., Elliss-Brookes, L., &
Gildea, C. (2021). Reviewing the impact of 11 national Be Clear on
Cancer public awareness campaigns, England, 2012 to 2016: A synthe-
sis of published evaluation results. International Journal of Cancer, 148,
1172–1182. https://doi.org/10.1002/ijc.33277
Lyratzopoulos, G., Wardle, J., & Rubin, G. (2014). Rethinking diagnostic
delay in cancer: How difficult is the diagnosis? BMJ, 349, g7400.
https://doi.org/10.1136/bmj.g7400
MacArtney, J., Malmstrom, M., Overgaard Nielsen, T., Evans, J.,
Bernhardson, B. M., Hajdarevic, S., & Ziebland, S. (2017). Patients' ini-
tial steps to cancer diagnosis in Denmark, England and Sweden: What
can a qualitative, cross-country comparison of narrative interviews tell
us about potentially modifiable factors? BMJ Open, 7(11), e018210.
https://doi.org/10.1136/bmjopen-2017-018210
Maringe, C., Walters, S., Rachet, B., Butler, J., Fields, T., Finan, P., & ICBP
Module 1 Working Group. (2013). Stage at diagnosis and colorectal
TORRANCE ET AL. 9 of 10
cancer survival in six high-income countries: A population-based
study of patients diagnosed during 2000-2007. Acta Oncology, 52(5),
919–932. https://doi.org/10.3109/0284186X.2013.764008
McAteer, A., Elliott, A. M., & Hannaford, P. C. (2011). Ascertaining the size
of the symptom iceberg in a UK-wide community-based survey. British
Journal of General Practice, 61(582), e1–e11. https://doi.org/10.3399/
bjgp11X548910
Moffat, J., Bentley, A., Ironmonger, L., Boughey, A., Radford, G., &
Duffy, S. (2015). The impact of national cancer awareness campaigns
for bowel and lung cancer symptoms on sociodemographic inequalities
in immediate key symptom awareness and GP attendances. British
Journal of Cancer, 112(Suppl 1), S14–S21. https://doi.org/10.1038/bjc.
2015.31
McCutchan, G. M., Wood, F., Edwards, A., Richards, R., & Brain, K. E.
(2015). Influences of cancer symptom knowledge, beliefs and barriers
on cancer symptom presentation in relation to socioeconomic depriva-
tion: a systematic review. BMC Cancer, 15, 1000. https://doi.org/10.
1186/s12885-015-1972-8




Public Health England. (2019). National Cancer Registration and Analysis
Service (NCRAS). Be Clear on Cancer evaluation metrics: methodol-
ogy. Crown copyright 2019. Available at: http://www.ncin.org.uk/
search/methodology
Quaresma, M., Coleman, M. P., & Rachet, B. (2015). 40-year trends in an
index of survival for all cancers combined and survival adjusted for age
and sex for each cancer in England and Wales, 1971-2011: A
population-based study. Lancet, 385(9974), 1206–1218. https://doi.
org/10.1016/S0140-6736(14)61396-9
NHS Digital. (2016). Read codes. https://digital.nhs.uk/services/
terminology-and-classifications/read-codes
Rendle, K. A., Sarma, E. A., Quaife, S. L., Blake, K. D., Moser, R. P.,
Suls, J. M., Edwards, H. M., & Kobrin, S. C. (2019). Cancer symptom
recognition and anticipated delays in seeking care among U.S. adults.
American Journal of Preventive Medicine, 57(1), e1–e9. https://doi.org/
10.1016/j.amepre.2019.02.021
Rubin, G., Berendsen, A., Crawford, S. M., Dommett, R., Earle, C.,
Emery, J., & Zimmermann, C. (2015). The expanding role of primary
care in cancer control. Lancet Oncology, 16(12), 1231–1272. https://
doi.org/10.1016/S1470-2045(15)00205-3
Scheel, B. I., & Holtedahl, K. (2015). Symptoms, signs, and tests: The
general practitioner's comprehensive approach towards a cancer diag-
nosis. Scandinavian Journal of Primary Health Care, 33(3), 170–177.
https://doi.org/10.3109/02813432.2015.1067512
Simon, A. E., Waller, J., Robb, K., & Wardle, J. (2010). Patient delay in pre-
sentation of possible cancer symptoms: The contribution of knowl-
edge and attitudes in a population sample from the United Kingdom.
Cancer Epidemiology Biomarkers Prevention, 19(9), 2272–2277. https://
doi.org/10.1158/1055-9965.EPI-10-0219
Smith, P., Smits, S., Owen, S., Wood, F., McCutchan, G., Carter, B., &
Brain, K. (2018). Feasibility and acceptability of a cancer symptom
awareness intervention for adults living in socioeconomically deprived
communities. BMC Public Health, 18(1), 695. https://doi.org/10.1186/
s12889-018-5606-3
The Health Improvement Network (THIN) database. (2017). Available at:
https://www.the-health-improvement-network.co.uk/
Walter, F. M., Emery, J. D., Mendonca, S., Hall, N., Morris, H. C.,
Mills, K., & Rubin, G. P. (2016). Symptoms and patient factors associ-
ated with longer time to diagnosis for colorectal cancer: results from a
prospective cohort study. British Journal of Cancer, 115(5), 533–541.
https://doi.org/10.1038/bjc.2016.221
Walter, F. M., Mills, K., Mendonca, S. C., Abel, G. A., Basu, B., Carroll, N., &
Emery, J. D. (2016). Symptoms and patient factors associated with
diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic
study): A prospective cohort study. Lancet Gastroenterology and
Hepatology, 1(4), 298–306. https://doi.org/10.1016/S2468-1253(16)
30079-6
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Torrance, N., Bright, C. J., Hill, H. L.,
Fergusson, J., Kennedy, C., Mak, V., Gildea, C., Nordin, A., &
Elliss-Brookes, L. (2021). Abdominal cancer symptoms:
Evaluation of the impact of a regional public awareness
campaign. European Journal of Cancer Care, e13500. https://
doi.org/10.1111/ecc.13500
10 of 10 TORRANCE ET AL.
